SCHEMBL6691985

SCHEMBL6691985

[CH2]Cn1ccc(-c2cccnc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 9/20 0.45
ALDH1A1 P00352 5/20 0.45
CYP3A4 P08684 4/20 0.45
CYP1A2 P05177 3/20 0.45
CYP2C19 P33261 3/20 0.43
CYP2E1 P05181 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2B6 P20813 2/20 0.43
FYN P06241 1/20 0.42
METAP2 P50579 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27535692 0.89 CYP2A6 (0.44) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL27487465 0.86 NAMPT (0.43) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL14405046 0.83 CYP2A6 (0.54) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL5016843 0.81 AR (0.45) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL4260991 0.81 FYN (0.43) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL4260988 0.81 CYP2A6 (0.43) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL5017240 0.81 CYP2A6 (0.43) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL14384100 0.80 CYP2A6 (0.43) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19
SCHEMBL27499559 0.79 DYRK1A (0.43) ALDH1A1FYNCYP11B1CYP11B2KDM4E
SCHEMBL5017381 0.78 NAMPT (0.42) CYP2A6ALDH1A1CYP3A4CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220120-A1 Novel anhydrolide derivatives having antibacterial activity VO NHA HUU (US) 2004-11-04 US claimed
WO-2004069854-A1 NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY ENANTA PHARMACEUTICALS. INC. (US) 2004-08-19 WO claimed
US-6720308-B1 Anhydrolide derivatives having antibacterial activity ENANTA PHARMACEUTICALS, INC. 2004-04-13 US claimed
CN-1234718-C New macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2006-01-04 CN disclosed
US-20040220120-A1 Novel anhydrolide derivatives having antibacterial activity VO NHA HUU (US) 2004-11-04 US disclosed
WO-2004069854-A1 NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY ENANTA PHARMACEUTICALS. INC. (US) 2004-08-19 WO disclosed
US-6720308-B1 Anhydrolide derivatives having antibacterial activity ENANTA PHARMACEUTICALS, INC. 2004-04-13 US disclosed
CN-1464880-A New macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-12-31 CN disclosed
EP-1313751-A1 NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY Basilea Pharmaceutica AG (CH) 2003-05-28 EP disclosed
WO-2002016380-A1 NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220120-A1 Novel anhydrolide derivatives having antibacterial activity GALE, GNE, GMDS CYP2A6 1059/4885ALDH1A1 1310/4885CYP3A4 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.